New advances in the treatment of non-Hodgkin lymphoma with monoclonal antibodies;Neue entwicklungen in der therapie von non-Hodgkin lymphomen mit monoklonalen antikorpern

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 27, 1999, Pages 842-847

  Buske, Christian ^a,b   Feuring Buske, M ^a   Unterhalt, M ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; RICIN;

CANCER IMMUNOTHERAPY; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHODGKIN LYMPHOMA; REVIEW; TREATMENT INDICATION;

EID: 0033538552     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024429     Document Type: Review

References (42)

1. Anderson, K. C., M. P. Bates, B. L. Slaughenhoupt, G. S. Pinkus, S. F. Schlossmann, L. M. Nadler: Expression of human B-cell associated antigens on leukemias and lymphomas. Blood 63 (1984), 1424-1433.
2. Amitage, J. O.: Treatment of non-Hodgkin's lymphoma. New Engl. J. Med. 328 (1992), 1023-1030.
3. Bierman, P. J., J. M. Vose, J. R. Anderson, M. R. Bishop, A. Kessinger, J. O. Armitage: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 15 (1997), 445-450.
4. Brown, S. I., R. A. Miller, S. J. Horning, D. Czerwinski, S. M. Hart, R. McElderry, T. Basham, R. A. Warnke, T. C. Merigan, R. Levy: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alphainterferon. Blood 73 (1989), 651-661.
5. Cabanillas, F., A. J. Grillo-Lopez, P. McLaughlin, B. K., Link, R. Leva, M. Czuczman, M. R. Heyman, M. Williams, V. Jain, I. Bence-Bruckler, A. D. Ho, J. Lister, J. Rogers, D. Shen, C. Varns: Anti-CD20 antibody (MAB), IDEC-C2B8: Clearance of bcl-2t (14, 18) positive cells from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular lymphoma (LG/FNHL). Blood 88 (Suppl. 1) (1996), 91a.
6. Coiffier, B., N. Ketterer, C. Haioun, F. Reyes, V. Diehl, H. Tilly, D. Ma, P. Johnson, A. Lister, H. Hiddemann, D. Crowther, R. Capdeville: A multicenter, randomized phase II study of rituximab (chimeric anti CD20 mAb) at two dosages in patients with relapsed or refractory intermediate or high-grade (IHG-NHL) or in elderly patients in first-line therapy. Blood 90 (Suppl. 1) (1997), 510a.
7. Corcoran, M. C., J. Eary, I. Bernstein, O. W. Press: Radioimmunotherapy strategies for non-Hodgkin's lymphoma. Ann. Oncol. 8 (Suppl. 1) (1997), 133-138.
8. Czuczman, M. S., D. J. Straus, C. R. Divgi, M. Graham, P. Garin-Chesa, R. Finn, J. Myers, L. J. Old, S. M. Larson, D. A. Scheinberg: Phase I dose escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 11 (1993), 11:2021-2029.
9. Davis, T., R. Levy, C. A. White, D. G. Maloney, B. Link, W. S. Velasquez, C. Varns, C. Gardner, A. J. Grillo-Lopez: Retreatments with RITUXANÖ (Rituximab. IDEC-C2B8) have significant efficiacy, do not cause hama and are aviable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood 90 (Suppl. 1) (1997), 509a.
10. Devesa, S. S., W. J. Blot, B. J. Stone, B. A. Miller, R. E. Tarone, J. F. Fraumeni Jr.: Recent cancer trends in the United States. J. Nat. Cancer Inst. 87 (1995), 175-182.
11. Epenetos, A. A., D. Snook, H. Durbin, P. M. Johnson, J. Taylor-Papadimitriou: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46 (1986), 3183-3191.
12. Grossbard, M. L., J. M. Lambert, V. S. Goldmacher, N. I., Spector, J. Kinsella, L. Eliseo, F. Coral, J. A. A. Taylor, W. A. Blattler, C. L. Epstein, I., M. Nadler: Anti-B4-blocked ricin. J. Clin. Oncol. 11 (1993), 726-737.
13. Grossbard, M. L., D. Niedzwiecki, L. M. Nadler, S. M. Fruchtman, M. Schuster, A. Pecora, H. M. Lazarus, J. Johnson, B. A. Peterson, D. D. Hurd: Anti-B4-blocked ricin (Anti-B4-bR) adjuvant therapy post-autologous bone marrow transplant (ABMT) (CALGB 9254): A phase III intergroup study. Proc. Amer. Soc. Clin. Oncol. 17 (1998), 3a.
14. Haagen, I.-A., A. J. Geerars, W. B. de Lau, M. R. Clark, R. J. van de Griend, B. J. Bast, B. C. de Gast: Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 84 (1994), 556-563.
15. Haioun, C., E. Lepage, C. Gisselbrecht, B. Coiffier, A. Bosly, H. Tilly, P. Morel, C. Nouvel, R. Herbrecht, M. F. D'Agay, P. Gaulard, F. Reyes: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. J. Clin. Oncol. 12 (1994), 2543-2551.
16. Hiddemann, W.: Non-Hodgkin's lymphomas - Current status of therapy and future perspectives. Europ. J. Cancer 31 (1995), 2141-2145.
17. Hsu, F. J., C. B. Casper, D. Czerwinsky, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, R. Levy: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma long-term results of a clinical trial. Blood 89 (1997), 3129-3135.
18. Jones, P. T., P. H. Dear, J. Foots, M. S. Neuberber, G. Winter: Replacing the complementarity - Determining regions in a human antibody with those from a mouse. Nature 321 (1986), 522-525.
19. Juweid, M., R. M. Sharkey, A. Markowitz, T. Behr, L. C. Swayne, R. Dunn, H. J. Hansen, J. Shevitz, S. O. Leung, A. D. Rubin: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti CD22 monoclonal antibody. Cancer Res. 55 (23 Suppl) (1995), 5899s-5907s.
20. Kaiser, U., L. Trümper, M. Pfreundschuh, K. Havemann: Behandlung aggressiver non-Hodgkin-lymphome. Internist 38 (1997), 135-142.
21. Kaminski, M. S., L. M. Fig, K. R. Zasadny, K. F. Koral, R. B. DelRosario, I. R. Francis, C. A. Hanson, D. P. Normolle, E. Mudgett, C. P. Liu, S. Moon, P. Scott, R. A. Miller, R. L. Wahl: Imaging, dosimetry, and radioimmunotherapy with iodine-131-labeled anti CD37 antibody in B-cell lymphoma. J. Clin. Oncol. 10 (1992), 1696-1711.
22. Kaminski, M. S., T. Gribbin, J. Estes, C. W. Ross, D. Regan, K. Zasadny, J. Tamminen, P. Kison, M. Tuck, S. Fisher, N. Petry, R. L. Wahl: I-131 Anti-B1 antibody for previously untreated follicular lymphoma (FL). Proc. Amer. Soc. Clin. Oncol. 17 (1998), 2a.
23. Kaminski, M. S., K. R. Zasadny, I. R. Francis, M. C. Fenner, C. W. Ross, A. W. Milik, J. Estes, M. Tuck, D. Regan, S. Fisher, S. D. Glenn, R. L. Wahl: Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14 (1996), 1974-1981.
24. 131I] anti-B1 (anti-CD20) antibody. New Engl. J. Med. 329 (1993), 459-465.
25. Kotz, D.: Alpha particle therapy poised to become new line of cancer treatment. J. Nucl. Med. 39 (1998), 17N-19N.
26. 486IL-2) in hematological malignancies expressing the IL-2 receptor. Blood 79 (1992), 2547-2554.
27. Link, B. K., M. L. Grossbard, R. I. Fisher, M. Czuczman, P. Gilman, A. M. Lowe, J. M. Vose: Phase II pilot study of the safety and efficiacy of rituximabin combination with CHOP chemotherapy in patients with previously untreated intermediate - Or high grade NHL. Proc. Amer. Soc. Clin. Oncol. 17 (1998), 3a.
28. LoBuglio, A. F., N. S. Mansoor: Advances in monoclonal antibody therapy of cancer. Amer. J. Med. Sci. 304 (1992), 214-224.
29. LoBuglio, A. F., R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, L. Sun, J. Grayeb, M. B. Khazaeli: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. 86 (1989), 4220-4224.
30. Maloney, D. G., A. J. Grillo-Lopez, D. Bodkin, C. A. White, T.-M. Liles, I. Royston, C. Varns, J. Rosenberg, R. Levy: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15 (1997), 3266-3274.
31. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, K. Wey, I. Royston, T. Davis, R. Levy: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188-2195.
32. Morrison, S. L.: Transfectomas provide novel chimeric antibodies. Science 229 (1986), 379-393.
33. Nichols, J., F. Foss, T. M. Kuzel, C. F. LeMaistre, L. Platanias, M. J. Ratain, A. Rook, M. Saleh, G. Schwartz: Interleukin-2 fusion protein: an investigated therapy for interleukin-2 receptor expressing malignancies. Europ. Cancer 33 (Suppl. 1) (1997), S34-S36.
34. Press, O. W., J. F. Eary, F. R. Appelbaum, P. J. Martin, C. C. Badger, W. B. Nelp, S. Glenn, G. Butchko, D. Fisher, B. Porter, D. C. Matthews, L. D. Fisher, I. D. Bernstein: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl. J. Med. 329 (1993), 1919-1924.
35. Press, O. W., J. F. Eary, F. R. Appelbaum, P. J. Martin, W. B. Nelp, S. Glenn, D. Fisher, B. Porter, D. C. Matthews, Golley et al.: Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995), 336-340.
36. Rogers, J., J. Jackson, J. Rosenberg, C. Varns, J. Leonard, A. J. Grillo-Lopez: Clearance of bel-2 (t14; 18), from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular (IWF: A-D) lymphoma (NHL) following single-agent therapy with the chimeric anti-CD20 antibody (MAB) IDEC-C2B8. Ann. Oncol. 7 (1996), 108a.
37. Roitt, L., J. Brostoff, D. Make: Immunology, 3rd Ed. (Gower medical Publishing London 1991)
38. 486IL-2, an IL-2-diphteria fusion toxin. Blood 78 (Suppl) (1991), 175a.
39. Stone, M. J., E. A. Sausville, J. W. Fay, D. Headlee, R. H. Collins, W. D. Figg, M. Stetler-Stevenson, V. Jain, E. S. Jaffe, D. Solomon, R. M. Lush, A. Senderowicz, V. Ghetie, J. Schindler, J. W. Uhr, E. S. Vitetta: A phase I study of bolus versus continous influsion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88 (1996), 1188-1197.
40. Stuschke, M., A. Hoederath, H. Sack et al.: Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centro-blastic-centrocytic lymphomas. Study Group NHL-fruhe Stadien. Cancer 80 (1997), 2273-2284.
41. Vitetta, E. S., R. J. Fulton, R. D. May, M. Till, J. W. I. Uhr: Redesigning nature's poisons to create antitumor reagents. Science 238 (1987), 1098-1104.
42. Vitetta, E.S., M. Stone, P. Amlot, J. Fay, R. May, M. Till, J. Newman, P. Clark, R. Collins, D. Cunningham: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51 (1991), 4052-4058.